Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ST. THOMAS, U.S. Virgin Islands; LAUSANNE, Switzerland; FT. LAUDERDALE, Fla.; and HAMILTON, Bermuda, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Auven Therapeutics, an international private equity company...
-
Ocular Technologies’ key development program asset, SecieraTM for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial Auven to receive $40 million upfront...
-
Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end Seciera poised for...
-
Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing Commercial assessment confirms Seciera has the potential for $1 billion in...
-
ST. THOMAS, U.S. Virgin Islands, LAUSANNE, Switzerland, HAMILTON, Bermuda and LAVAL, Quebec, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Auven Therapeutics, a global private equity company focused on...
-
Seciera demonstrated significant improvements in tear production and ocular surface inflammation Additional pivotal Phase 3 study planned for early 2016 ST. THOMAS, U.S. Virgin Islands,...